Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. more
Time Frame | AZN | Sector | S&P500 |
---|---|---|---|
1-Week Return | -0.82% | -0.33% | -1.49% |
1-Month Return | 0.35% | -4.57% | -0.37% |
3-Month Return | -13.32% | -9.96% | 3.89% |
6-Month Return | -16.05% | -5.67% | 9.34% |
1-Year Return | 0.2% | 2.53% | 25.19% |
3-Year Return | 14.76% | -1.43% | 24.7% |
5-Year Return | 33.61% | 34.73% | 85.39% |
10-Year Return | 89.18% | 102.14% | 187.19% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 24.38B | 26.62B | 37.42B | 44.35B | 45.81B | [{"date":"2019-12-31","value":53.23,"profit":true},{"date":"2020-12-31","value":58.1,"profit":true},{"date":"2021-12-31","value":81.68,"profit":true},{"date":"2022-12-31","value":96.81,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 4.92B | 5.30B | 12.44B | 12.39B | 8.04B | [{"date":"2019-12-31","value":39.57,"profit":true},{"date":"2020-12-31","value":42.61,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.63,"profit":true},{"date":"2023-12-31","value":64.65,"profit":true}] |
Gross Profit | 19.46B | 21.32B | 24.98B | 31.96B | 37.77B | [{"date":"2019-12-31","value":51.53,"profit":true},{"date":"2020-12-31","value":56.44,"profit":true},{"date":"2021-12-31","value":66.14,"profit":true},{"date":"2022-12-31","value":84.62,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 79.82% | 80.09% | 66.76% | 72.06% | 82.45% | [{"date":"2019-12-31","value":96.81,"profit":true},{"date":"2020-12-31","value":97.14,"profit":true},{"date":"2021-12-31","value":80.97,"profit":true},{"date":"2022-12-31","value":87.4,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 16.27B | 16.16B | 23.92B | 28.20B | 29.58B | [{"date":"2019-12-31","value":54.99,"profit":true},{"date":"2020-12-31","value":54.62,"profit":true},{"date":"2021-12-31","value":80.88,"profit":true},{"date":"2022-12-31","value":95.35,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | 2.92B | 5.16B | 1.06B | 3.76B | 8.19B | [{"date":"2019-12-31","value":35.69,"profit":true},{"date":"2020-12-31","value":63.01,"profit":true},{"date":"2021-12-31","value":12.89,"profit":true},{"date":"2022-12-31","value":45.86,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Total Non-Operating Income/Expense | (2.61B) | (2.46B) | (2.58B) | (2.51B) | (2.58B) | [{"date":"2019-12-31","value":-261300000000,"profit":false},{"date":"2020-12-31","value":-246500000000,"profit":false},{"date":"2021-12-31","value":-257800000000,"profit":false},{"date":"2022-12-31","value":-250700000000,"profit":false},{"date":"2023-12-31","value":-258200000000,"profit":false}] |
Pre-Tax Income | 1.55B | 3.92B | (265.00M) | 2.50B | 6.90B | [{"date":"2019-12-31","value":22.44,"profit":true},{"date":"2020-12-31","value":56.76,"profit":true},{"date":"2021-12-31","value":-3.84,"profit":false},{"date":"2022-12-31","value":36.25,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income Taxes | 321.00M | 772.00M | (380.00M) | (792.00M) | 938.00M | [{"date":"2019-12-31","value":34.22,"profit":true},{"date":"2020-12-31","value":82.3,"profit":true},{"date":"2021-12-31","value":-40.51,"profit":false},{"date":"2022-12-31","value":-84.43,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | 1.23B | 3.14B | 115.00M | 3.29B | 5.96B | [{"date":"2019-12-31","value":20.58,"profit":true},{"date":"2020-12-31","value":52.74,"profit":true},{"date":"2021-12-31","value":1.93,"profit":true},{"date":"2022-12-31","value":55.24,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income From Continuous Operations | 1.23B | 3.14B | 115.00M | 3.29B | 5.96B | [{"date":"2019-12-31","value":20.58,"profit":true},{"date":"2020-12-31","value":52.74,"profit":true},{"date":"2021-12-31","value":1.93,"profit":true},{"date":"2022-12-31","value":55.24,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 1.33B | 3.20B | 112.00M | 3.29B | 5.96B | [{"date":"2019-12-31","value":22.42,"profit":true},{"date":"2020-12-31","value":53.67,"profit":true},{"date":"2021-12-31","value":1.88,"profit":true},{"date":"2022-12-31","value":55.21,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
EPS (Diluted) | 1.77 | 2.02 | 2.65 | 3.34 | 3.64 | [{"date":"2019-12-31","value":48.63,"profit":true},{"date":"2020-12-31","value":55.49,"profit":true},{"date":"2021-12-31","value":72.8,"profit":true},{"date":"2022-12-31","value":91.76,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
AZN | |
---|---|
Cash Ratio | 0.19 |
Current Ratio | 0.93 |
Quick Ratio | 0.71 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
AZN | |
---|---|
ROA (LTM) | 8.50% |
ROE (LTM) | 16.66% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
AZN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.61 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.39 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
AZN | |
---|---|
Trailing PE | 32.19 |
Forward PE | 14.24 |
P/S (TTM) | 4.03 |
P/B | 5.07 |
Price/FCF | 102 |
EV/R | 4.49 |
EV/Ebitda | 15.45 |
PEG | 0.71 |
AstraZeneca PLC ADR (AZN) share price today is $66.3
Yes, Indians can buy shares of AstraZeneca PLC ADR (AZN) on Vested. To buy AstraZeneca PLC ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in AZN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of AstraZeneca PLC ADR (AZN) via the Vested app. You can start investing in AstraZeneca PLC ADR (AZN) with a minimum investment of $1.
You can invest in shares of AstraZeneca PLC ADR (AZN) via Vested in three simple steps:
The 52-week high price of AstraZeneca PLC ADR (AZN) is $87.67. The 52-week low price of AstraZeneca PLC ADR (AZN) is $59.19.
The price-to-earnings (P/E) ratio of AstraZeneca PLC ADR (AZN) is 32.1884
The price-to-book (P/B) ratio of AstraZeneca PLC ADR (AZN) is 5.07
The dividend yield of AstraZeneca PLC ADR (AZN) is 2.27%
The market capitalization of AstraZeneca PLC ADR (AZN) is $206.59B
The stock symbol (or ticker) of AstraZeneca PLC ADR is AZN